价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价狙击礼来(LLY.US)夺回市场

智通财经02-24

智通财经APP获悉，诺和诺德(NVO.US)计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美国官方定价，以在肥胖症治疗市场争夺更大份额。这家丹麦药企将司美格鲁肽全系列药物月均统一定价为675美元，降幅高达50%。其美国竞争对手礼来(LLY.US)的同类减肥药物Zepbound，目前官方定价为1086.37美元/月。此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2613712854?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-24 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613712854","market":"fut","top_or_hot":-1,"title":"价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价 狙击礼来(LLY.US)夺回市场","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，诺和诺德(NVO.US)计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美国官方定价，以在肥胖症治疗市场争夺更大份额。这家丹麦药企将司美格鲁肽全系列药物月均统一定价为675美元，降幅高达50%。其美国竞争对手礼来(LLY.US)的同类减肥药物Zepbound，目前官方定价为1086.37美元/月。此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1406860.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价 狙击礼来(LLY.US)夺回市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价 狙击礼来(LLY.US)夺回市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-24 21:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1406860.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，诺和诺德(NVO.US)计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美国官方定价，以在肥胖症治疗市场争夺更大份额。这家丹麦药企将司美格鲁肽全系列药物月均统一定价为675美元，降幅高达50%。其美国竞争对手礼来(LLY.US)的同类减肥药物Zepbound，目前官方定价为1086.37美元/月。此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1406860.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1406860.html","article_id":"2613712854","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613712854","pubTimestamp":1771939893,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，诺和诺德计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美国官方定价，以在肥胖症治疗市场争夺更大份额。此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的返利体系。目前，诺和诺德正在价格方面多措并举，以提升在肥胖症领域的竞争力。新价格将于明年1月1日生效。Millar表示，公司需要现在宣布降价，以便让付款方有时间应对明年的变化。Millar强调，两次降价相互独立，并无关联。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4599":"减肥药","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","ELIL":"2倍做多LLY ETF-Direxion","LU1917777945.USD":"安联专题基金Cl AT Acc","LLII":"REX LLY Growth & Income ETF","LU0238689110.USD":"贝莱德环球动力股票基金","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","ELIS":"1倍做空LLY ETF-Direxion","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LLYX":"2倍做多LLY ETF-Defiance","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LLYZ":"2倍做空LLY ETF-Defiance","NVOX":"2倍做多NVO ETF-Defiance","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","LLY":"礼来","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BK4007":"制药","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","NVO":"诺和诺德"},"translate_title":"The price war begins! Novo Nordisk (NVO.US) will significantly cut the price of weight-loss pills in the United States starting next year to attack Eli Lilly (LLY.US) to regain the market","themeId":"b9030c47a641b4d32c695499220ff2c5","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELIS":0.6,"LLYZ":0.6,"NVOX":0.6,"ELIL":0.6,"LLY":1.5,"LLYX":0.6,"NVO":1.5,"LLII":0.6,"NVOH":0.6},"content_text":"智通财经APP获悉，诺和诺德(NVO.US)计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美国官方定价，以在肥胖症治疗市场争夺更大份额。这家丹麦药企将司美格鲁肽全系列药物月均统一定价为675美元，降幅高达50%。其美国竞争对手礼来(LLY.US)的同类减肥药物Zepbound，目前官方定价为1086.37美元/月。此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的返利体系。在商业保险层面，患者使用Zepbound与Wegovy每月自付费用最低可至25美元。诺和诺德美国区负责人Jamey Millar表示，本次降价不适用于美国现有自费价格，但可减轻部分保险患者的自付负担——尤其是那些需按较高比例承担药费的参保人群。“我相信支付方会接受并欢迎此次降价，他们此前已公开呼吁降低药价，”Millar称，单独来看，此举不会影响公司净销售额。目前，诺和诺德正在价格方面多措并举，以提升在肥胖症领域的竞争力。Millar曾任职于联合健康(UNH.US)旗下药品福利管理机构Optum Rx，是美国定价策略方面的专家。新价格将于明年1月1日生效。Millar表示，公司需要现在宣布降价，以便让付款方有时间应对明年的变化。他指出，此次调整对高免赔额保险人群影响尤为明显——这类保单的自付费用与官方定价高度挂钩;按药品定价比例付费的共付保险患者，同样将受益。据KFF的雇主健康福利调查，去年约三分之一参保职工选择了高免赔额医保搭配个人健康储蓄账户方案;调查同时显示，不到一半的大型企业为Wegovy这类GLP-1减重药物提供医保报销。本次官方降价，将与美国政府去年为联邦医疗保险(针对老年人的联邦保险计划)患者谈判达成的优惠同步实施。Millar强调，两次降价相互独立，并无关联。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613712854","isCrawlerRequest":true}

价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价 狙击礼来(LLY.US)夺回市场

精彩评论

价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价狙击礼来(LLY.US)夺回市场